Table 1 Demographic and clinicopathological data of 215 patients with major salivary gland carcinoma
From: Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis
Variable | Number of patients (%) | |
|---|---|---|
Total = 215 | ||
Morphology | Acinic carcinoma | 62 (28.84 %) |
Adenocarcinoma | 19 (8.84 %) | |
Adenoid cystic carcinoma | 20 (9.30 %) | |
Basal cell adenocarcinoma | 7 (3.26 %) | |
Carcinoma-ex pleomorphic | 18 (8.37 %) | |
Mucoepidermoid carcinoma | 70 (32.56 %) | |
Salivary duct carcinoma | 19 (8.84 %) | |
Pathological Tumor classification | T1 | 68 (34.17 %) |
T2 | 61 (30.65 %) | |
T3 | 48 (24.12 %) | |
T4a | 20 (10.05 %) | |
T4b | 2 (1.01 %) | |
na | 16 (7.44 %) | |
Pathological Lymph node status | N0 | 126 (70.79 %) |
N+ | 52 (29.21 %) | |
na | 37 (17.2 %) | |
Pathological Staging | I | 64 (33.51 %) |
II | 46 (24.08 %) | |
III | 40 (20.94 %) | |
IVa | 41 (21.47 %) | |
na | 24 (11.16 %) | |
Pathological Grading | I | 94 (45.41 %) |
II | 34 (16.43 %) | |
III | 79 (38.16 %) | |
na | 8 (3.72 %) | |
Margin status | negative | 121 (61.11 %) |
positive | 77 (38.89 %) | |
na | 17 (7.90 %) | |
Perineural invasion | negative | 144 (73.10 %) |
positive | 53 (26.90 %) | |
na | 18 (8.37 %) | |
Lymphovascular invasion | negative | 154 (79.38 %) |
positive | 40 (20.62 %) | |
na | 21 (9.76 %) | |
Extracapsular extension | negative | 169 (88.48 %) |
positive | 22 (11.52 %) | |
na | 24 (11.16 %) | |
Periparotid lymph node involvement | negative | 167 (82.67 %) |
positive | 35 (17.33 %) | |
na | 13 (6.04 %) |